Abstract
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2905-2914 |
| Number of pages | 10 |
| Journal | Future Oncology |
| Volume | 15 |
| Issue number | 25 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
Keywords
- afatinib
- NSCLC
- osimertinib
- sequential
- T790M
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : Updated analysis of the observational GioTag study. / Hochmair, Maximilian J.; Morabito, Alessandro; Hao, Desiree; Yang, Cheng Ta; Soo, Ross A.; Yang, James C.H.; Gucalp, Rasim A.; Halmos, Balazs; Wang, Lara; Märten, Angela; Cufer, Tanja.
In: Future Oncology, Vol. 15, No. 25, 01.01.2019, p. 2905-2914.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
T2 - Updated analysis of the observational GioTag study
AU - Hochmair, Maximilian J.
AU - Morabito, Alessandro
AU - Hao, Desiree
AU - Yang, Cheng Ta
AU - Soo, Ross A.
AU - Yang, James C.H.
AU - Gucalp, Rasim A.
AU - Halmos, Balazs
AU - Wang, Lara
AU - Märten, Angela
AU - Cufer, Tanja
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.
AB - Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT0337077.
KW - afatinib
KW - NSCLC
KW - osimertinib
KW - sequential
KW - T790M
UR - http://www.scopus.com/inward/record.url?scp=85071633846&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071633846&partnerID=8YFLogxK
U2 - 10.2217/fon-2019-0346
DO - 10.2217/fon-2019-0346
M3 - Review article
C2 - 31370698
AN - SCOPUS:85071633846
VL - 15
SP - 2905
EP - 2914
JO - Future Oncology
JF - Future Oncology
SN - 1479-6694
IS - 25
ER -